IceCure Medical Ltd (NASDAQ:ICCM) Short Interest Down 6.1% in September

IceCure Medical Ltd (NASDAQ:ICCM) saw a significant decline in short interest in September. As of September 30th, there was short interest totalling 369,000 shares, a decline of 6.1% from the September 15th total of 393,100 shares. Currently, 1.5% of the company’s stock are sold short. Based on an average daily trading volume, of 579,100 shares, the short-interest ratio is presently 0.6 days.

Wall Street Analyst Weigh In

Separately, HC Wainwright reaffirmed a “buy” rating and set a $2.50 target price on shares of IceCure Medical in a research report on Thursday, September 12th.

IceCure Medical Stock Down 6.8 %

IceCure Medical stock traded down $0.04 during trading hours on Wednesday, reaching $0.54. The stock had a trading volume of 739,917 shares, compared to its average volume of 509,851. IceCure Medical has a 52 week low of $0.48 and a 52 week high of $1.57. The company has a market cap of $24.65 million, a price-to-earnings ratio of -1.76 and a beta of 0.56. The company has a debt-to-equity ratio of 0.03, a current ratio of 2.97 and a quick ratio of 2.54. The business’s 50 day moving average price is $0.63 and its 200-day moving average price is $0.84.

IceCure Medical (NASDAQ:ICCM) last posted its quarterly earnings data on Tuesday, August 20th. The company reported ($0.06) EPS for the quarter, topping the consensus estimate of ($0.07) by $0.01. IceCure Medical had a negative net margin of 410.22% and a negative return on equity of 111.27%. The firm had revenue of $1.01 million during the quarter, compared to analyst estimates of $0.90 million. During the same quarter in the previous year, the business posted ($0.09) EPS. Sell-side analysts anticipate that IceCure Medical will post -0.27 EPS for the current year.

Institutional Inflows and Outflows

An institutional investor recently bought a new stake in IceCure Medical stock. Renaissance Technologies LLC purchased a new position in shares of IceCure Medical Ltd (NASDAQ:ICCM) during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 66,400 shares of the company’s stock, valued at approximately $49,000. Renaissance Technologies LLC owned about 0.15% of IceCure Medical as of its most recent filing with the Securities & Exchange Commission. Hedge funds and other institutional investors own 0.62% of the company’s stock.

IceCure Medical Company Profile

IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors. The company offers ProSense system, a single probe system for the treatment of tumors, as well as associated disposables; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology.